American biotech giant focused on neurological diseases
A body of studies is showing that a blood marker called p-tau217 can forecast an elevated risk of cognitive impairment in healthy older adults years before symptoms appear. The evidence is not yet clinical-ready, but it is guiding trials that aim to slow or prevent Alzheimer’s disease and is being tested in Scotland’s primary care setting.